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INTRODUCTION 
The gastric emptying of dosage forms is an extremely 
variable process and ability to prolong and control the 
emptying time is a valuable asset for dosage forms that 
reside in the stomach for a longer period of time than 
conventional dosage forms. There are many difficulties 
faced in designing controlled release systems for better 
absorption and enhanced bioavailability. One of such 
difficulties is the inability to confine the dosage form in 
the desired area of the gastrointestinal tract. Drug 
absorption from the gastrointestinal tract is a complex 
procedure and is subject to many variables. It is widely 
acknowledged that the extent of gastrointestinal tract 
drug absorption is related to contact time with the small 
intestinal mucosa. Thus, small intestinal transit time is an 
important parameter for drugs that are incompletely 
absorbed. Basic human physiology with the details of 
gastro intestinal retention, motility patterns, and 
physiological and formulation variables affecting the 
gastric emptying are summarized.1- 2  
GASTROINTESTINAL RETENTION 
Gastro retentive can be remain in gastric region for 
several hours and hence significantly prolong the gastric 
residence time of drugs. Prolonged gastric retention 
improves bioavailability, reduces drug wastage and 
improves solubility of drugs that are less soluble in a 
high pH environment.3 
It has application also for local drug delivery to the 
stomach and proximal small intestine. Gastro retention 
helps to provide better availability of new products with 
new therapeutic possibilities and substantial benefits to 
patients.4 
To successfully modulate the gastro intestinal transit 
time of a drug delivery system through floating drug 
delivery system for maximal gastrointestinal absorption 
of drugs and site specific delivery, one needs to have a 
good fundamental understanding of the anatomic and 
physiological characteristics of the human GIT.5 
 GASTROINTESTINAL TRACT PHYSIOLOGY 
The main function of the stomach is to process and 
transport food. It serves as a short term storage reservoir, 
allowing a rather large meal to be consumed quickly. 
Substantial enzymatic digestion is initiated in stomach, 
particularly of proteins. Vigorous contraction of gastric 
smooth muscle mixes and grinds food stuffs with gastric 
secretions, resulting in liquefaction of food. As food is 
liquefied in the stomach, it is slowly released into small 
intestine for further processing.6 
Basically stomach is divided into 3 regions: fundus, 
body, and antrum (pylorus). The proximal part made of 
fundus and body acts as a reservoir for undigested 
material, the antrum is the main site for mixing motions 
and act as a pump for gastric emptying by propelling 
actions.7 Gastric emptying occurs during fasting as well 
as fed states. The pattern of motility is however distinct 
in the 2 states. During the fasting state an inter-digestive 
series of electrical events take place, which cycle both 
through stomach and intestine every 2 to 3 hours.8 This is 
called the inter-digestive myloelectric cycle or migrating 
myloelectric cycle (MMC), which is further divided into 
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following 4 phases as described by Wilson and 
Washington.9   
Phase I (basal phase) lasts from 40 to 60 minutes with 
rare contractions.    
Phase II (pre-burst phase) lasts for 40 to 60 minutes with 
intermittent action potential and contractions. As the 
phase progresses the intensity and frequency also 
increases gradually.  
Phase III (burst phase) lasts for 4 to 6 minutes. It 
includes intense and regular contractions for short 
period. It is due to this wave that all the undigested 
material is swept out of the stomach down to the small 
intestine. It is also known as the housekeeper wave.  
Phase IV lasts for 0 to 5 minutes and occurs between 
phases III and I of 2 consecutive cycles. 
After the ingestion of a mixed meal, the pattern of 
contractions changes from fasted to that of fed state. This 
is also known as digestive motility pattern and comprises 
continuous contractions as in phase II of fasted state. 
These contractions result in reducing the size of food 
particles (to less than 1 mm), which are propelled toward 
the pylorus in a suspension form. During the fed state 
onset of MMC is delayed resulting in slowdown of 
gastric emptying rate. Scintigraphic studies determining 
gastric emptying rates revealed that orally administered 
controlled release dosage forms are subjected to basically 
2 complications, that of short gastric residence time and 
unpredictable gastric emptying rate.10    
 
FACTORS AFFECTING GASTRIC RESIDENCE T
IME OF FDDS  
The gastric retention time (GRT) of dosage form is 
controlled by several factors that affect their efficacy as a 
gastro retentive system.  
 Density – GRT is a function of dosage form 
buoyancy that is dependent on the density.11  
 Size – Dosage form units with a diameter of more 
than 9.5mm are reported to have an increased 
GRT.12  
 Shape of dosage form – Tetrahedron and ring-
shaped devices with a flexural modulus of 48 and 
22.5 kilo pounds per square inch (KSI) are reported 
to have better GRT. 90% to 100% retention at 24 
hours compared with other shapes.  
 Single or multiple unit formulation – Multiple unit 
formulations show a more predictable release profile 
and insignificant impairing of performance due to 
failure of units, allow co- administration of units 
with different release profiles or containing 
incompatible substances and permit a larger margin 
of safety against dosage form failure compared with 
single unit dosage forms.  
 Fed or unfed state – Under fasting conditions, the 
GI motility is characterized by periods of strong 
motor activity or the migrating myoelectric complex 
(MMC) that occurs every 1.5 to 2 hours. The MMC 
sweeps undigested material from the stomach and, if 
the timing of administration of the formulation 
coincides with that of the MMC, the GRT of the unit 
can be expected to be very short. However, in the 
fed state, MMC is delayed and GRT is considerably 
longer.   
 Nature of meal – Feeding of indigestible polymers 
or fatty acid salts can change the motility pattern of 
the stomach to a fed state, thus decreasing the gastric 
emptying rate and prolonging drug release.  
 Caloric content – GRT can be increased by four to 
10 hours with a meal that is high in proteins and 
fats.13   
 Frequency of feed – The GRT can increase by over 
400 minutes when successive meals are given 
compared with a single meal due to the low 
frequency of MMC.  
 Gender – Mean ambulatory GRT in males (3.4±0.6 
hours) is less compared with their age and race-
matched female counterparts (4.6±1.2 hours), 
regardless of the weight, height and body surface.  
 Age – Elderly people, especially those over 70, have 
a significantly longer GRT.  
 Posture – GRT can vary between supine and upright 
ambulatory states of the patient.14 
 Concomitant drug administration– 
Anticholinergics like Atropine and Propantheline, 
Opiates like Codeine and Prokinetic agents like 
Metoclopramide and Cisapride.  
 Biological factors – Diabetes and Crohn‟s disease. 
 
 
SUITABLE DRUGS FOR GASTRORETENTION
15
   
Delivery of the Drugs in continuous and controlled mann
er have a  lower level of side effects and provide their eff
ects without the need for repeated dosing  with  a  low do
sage frequency.Sustained release in the stomach is also u
seful for therapeutic agents that the  stomach  does   not r
eadily absorb, since sustained release prolongs the contac
t  time  of  the  agent  in  the     stomach or in the upper p
art of the small intestine, from where absorption occurs a
nd contact time   is  limited.  Appropriate candidates for 
controlled release gastroretentive dosage forms are 
molecules that have poor colonic absorption but are 
characterized by better absorption properties at the upper 
parts of the GIT.   
 Narrow absorption window in GI tract, e.g., riboflav
in and  levodopa  
Parveen et al                                     Journal of Drug Delivery & Therapeutics; 2014, 4(3), 14-24 16 
© 2011-14, JDDT. All Rights Reserved                                                ISSN: 2250-1177                                                CODEN (USA): JDDTAO 
 Basically absorbed from stomach  and  upper  part  o
f  GIT,  e.g.,  chlordiazepoxide and    cinnarazine.   
 Drugs that disturb  normal  colonic  bacteria,  e.g.,  a
moxicillin  trihydrate.   
 Locally active in the stomach, e.g., antacids and mis
oprostol.   
 Drugs  that  degrade  in  the  colon,  e.g.,  ranitidine  
HCl  and  metronidazole.  
 
 
APPROACHES TO GASTRORETENTION   
 
 
Several  techniques  are  reported  in  the  literature  to  in
crease  the  gastric retention of drugs.   
1) High-density systems    
These systems, which have a density of ~3g/cm3, are ret
ained in the   stomach  and   capableof  withstanding  its  
peristaltic  movements.  The only major   drawback   wit
h  the    systems is that it is technically difficult to manuf
acture them with a large amount of drug (>50%) and achi
eve  required  density  of 2.4‐2.8g/cm3.Diluents  such  a 
barium sulphate(density= 4.9),zinc oxide, titanium oxide,
 and iron powder  must be  used  to manufacture  such  hi
ghdensityformulation.16 
2) Swelling and expanding systems   
These  systems  are  also  called  as  “Plug  type  system”
, since they  exhibit tendency to remain logged in the 
pyloric sphincters. These polymeric matrices remain in t
he gastric cavity for several hours even in fed state.  
By  selection  of  polymer  with  the  proper  molecular  
weight  and  swelling properties controlled  and sustained
drug release can be  achieved. Upon coming in contact w
ith gastric fluid, the polymer imbibes water and swells. T
he extensive swelling of  these  polymers is a   result of t
he presence of physical‐chemical cross links in the hydro
philic polymer network. 
These cross link prevents the dissolution of polymer and 
thus maintain the physical integrity of  the dosage form. 
A high degree of cross linking retards the swelling  abilit
y  of  the  system  and  maintains  its  physical  integrity  
for  prolongedperiod. On the other hand, a low degree of 
cross linking  results in extensive swelling followed by th
e rapid dissolution of polymer.    
3) Incorporating delaying excipients   
Another  delayed  gastric  emptying  approach  of  interes
t  include  feeding of digestible  polymers or fatty acid sa
lts that charges the  motility pattern, of the stomach to a f
ed stage thereby decreasing the  gastric emptying rate an
d permitting considerable prolongation of  the    drug  rel
ease.  Prolongation  of  GRT  of  drug  delivery  system  
consists  of  incorporating   delaying  excipients  like  trie
tanolamine  myristate in a delivery system.17   
4) Modified systems   
Systems  with  non  disintegrating  geometric  shape  mo
ulded  from  silastic  elastomers  or  extruded from  polye
thylene  blends,  which  extend the GRT depending on si
ze, shape and    flexural modules ofdrug delivery device.1
8  
  
5) Mucoadhesive & bioadhesive systems   
Bioadhesive drug delivery systems are used to localize a 
delivery device within the lumen to enhance the drug abs
orption in a site‐specific manner.  This approach involves
 the use  of      bioadhesive  polymers, which can adhere t
o the epithelial surface in the stomach.  Some  of    the  m
ost  promising  excipients  that  have  been  used  commo
nly in these systems include   polycarbophil, carbopol, le
ctins,  chitosan, CMC and gliadin, etc.  
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6) Floating systems   
Floating drug delivery systems (FDDS) have a bulk dens
ity less than  gastric  fluids  and  so  remain  buoyant  in  
the  stomach  without  affecting the gastric emptying rate
 for a prolongedperiod of time.While  the  system  is  floa
ting  on  the gastric contents, the drug is releasedslowly a
t the desired rate from the system. After releaseof drug, t
he residual system is emptied from the stomach. Floatati
on of a drug delivery system in the stomach can be 
achieved by incorporating floating chamber filled 
with vacuum, air, or inert gas.19  
 
CLASSIFICATION OF FLOATING DRUG 
DELIVERY SYSTEM  
A. Single Unit Floating Dosage Systems  
a) Effervescent Systems (Gas-generating Systems)  
b) Non-effervescent Systems  
B. Multiple Unit Floating Dosage Systems  
a) Non-effervescent Systems  
b) Effervescent Systems (Gas-generating Systems)  
c) Hollow Microspheres  
C. Raft Forming Systems   
 
A. Single Unit Floating Dosage Systems  
a) Effervescent Systems (Gas-generating Systems)  
These buoyant systems utilized matrices prepared with 
swellable polymers like HPMC, polysaccharides like 
chitosan, effervescent components like sodium 
bicarbonate, citric acid and tartaric acid or chambers 
containing a liquid that gasifies at body temperature. The 
optimal stoichiometric ratio of citric acid and sodium 
bicarbonate for gas generation is reported to be 0.76:1. 
The common approach for preparing these systems 
involves resin beads loaded with bicarbonate and coated 
with ethylcellulose. The coating, which is insoluble but 
permeable, allows permeation of water. Thus, carbon 
dioxide is released, causing the beads to float in the 
stomach. Excipients used most commonly in these 
systems include HPMC, polyacrylate polymers, 
polyvinyl acetate, Carbopol®, agar, sodium alginate, 
calcium chloride, polyethylene oxide and 
polycarbonates.20  
b) Non-Effervescent Systems  
This type of system, after swallowing, swells 
unrestrained via imbibitions of gastric fluid to an extent 
that it prevents their exit from the stomach. These 
systems may be referred to as the „plug-type systems‟ 
since they have a tendency to remain lodged near the 
pyloric sphincter. One of the formulation methods of 
such dosage forms involves the mixing of drug with a 
gel, which swells in contact with gastric fluid after oral 
administration and maintains a relative integrity of shape 
and a bulk density of less than one within the outer 
gelatinous barrier. The air trapped by the swollen 
polymer confers buoyancy to these dosage forms. 
Examples of this type of FDDS include colloidal gel 
barrier, micro porous compartment system , alginate 
beads, and hollow microspheres. Another type is a Fluid- 
filled floating chamber which includes incorporation of a 
gas-filled floatation chamber into a micro porous 
component that houses a drug reservoir. Apertures or 
openings are present along the top and bottom walls 
through which the gastrointestinal tract fluid enters to 
dissolve the drug. The other two walls in contact with the 
fluid are sealed so that the undissolved drug remains 
therein. The fluid present could be air, under partial 
vacuum or any other suitable gas, liquid, or solid having 
an appropriate specific gravity and an inert behaviour. 
The device is of swallowable size, remains afloat within 
the stomach for a prolonged time and after the complete 
release the shell disintegrates, passes off to the intestine, 
and is eliminated.  A newer self-correcting floatable 
asymmetric configuration drug delivery system has a 3-
layermatrix to control the drug release. This 3-layer 
principle has been improved by development of an 
asymmetric configuration drug delivery system in order 
to modulate the release extent and achieve zero-order 
release kinetics by initially maintaining a constant area at 
the diffusing front with subsequent dissolution/erosion 
toward the completion of the release process. The system 
was designed in such a manner that it floated to prolong 
gastric residence time in vivo, resulting in longer total 
transit time within the gastrointestinal tract environment 
with maximum absorptive capacity and consequently 
greater bioavailability. This particular characteristic 
would be applicable to drugs that have pH-dependent 
solubility, a narrow window of absorption, and are 
absorbed by active transport from either the proximal or 
distal portion of the small intestine.7, 20  
B. Multiple Unit Floating Systems  
In spite of extensive research and development in the 
area of hydro dynamically balanced systems and other 
floating tablets, these systems suffer from an important 
drawback of high variability of gastrointestinal transit 
time, when orally administered, because of their all-or-
nothing gastric emptying nature. In order to overcome 
the above problem, multiple unit floating systems were 
developed, which reduce the inter-subject variability in 
absorption and lower the probability of dose- dumping. 
Reports have been found on the development of both 
non-effervescent and effervescent multiple unit systems . 
Much research has been focused and the scientists are 
still exploring the field of hollow microspheres, capable 
of floating on the gastric fluid and having improved 
gastric retention properties.21   
a) Non-effervescent Systems  
No much report was found in the literature on non- 
effervescent multiple unit systems, as compared to the 
effervescent systems. However, few workers have 
reported the possibility of developing such system 
containing indomethacin, using chitosan as the polymeric 
excipient. A multiple unit HBS containing indomethacin 
as a model drug prepared by extrusion process is 
reported. A mixture of drug, chitosan and acetic acid is 
extruded through a needle, and the extrudate is cut and 
dried. Chitosan hydrates and floats in the acidic media, 
and the required drug release could be obtained by 
modifying the drug-polymer ratio.22   
b) Effervescent Systems (Gas-generating Systems)  
There are reports of sustained release floating granules 
containing tetracycline hydrochloride. The granules are a 
mixture of drug granulates of two stages A and B, of 
which A contains 60 parts of HPMC, 40 parts of 
polyacrylic acid and 20 parts of drug and B contains 70 
parts of sodium bicarbonate and 30 parts of tartaric acid. 
60 parts by weight of granules of stage A and 30 parts by 
weight of granules of stage B are mixed along with a 
lubricant and filled into capsule. In dissolution media, 
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the capsule shell dissolves and liberates the granules, 
which showed a floating time of more than 8 h and 
sustained drug release of 80% in about6.5 h. Floating 
minicapsules of pepstatin having a diameter of 0.1-0.2 
mm has been reported by Umezawa. These minicapsules 
contain a central core and a coating. The central core 
consists of a granule composed of sodium bicarbonate, 
lactose and a binder, which is coated with HPMC. 
Pepstatin is coated on the top of the HPMC layer. The 
system floats because of the CO2 release in gastric fluid 
and the pepstatin resides in the stomach for prolonged 
period. Alginates have received much attention in the 
development of multiple unit systems. Alginates are non-
toxic, biodegradable linear copolymers composed of L- 
glucuronic and L-mannuronic acid residues. A multiple 
unit system was prepared comprises of calcium alginate 
core and calcium alginate/PVA membrane, both 
separated by an air compartment. In presence of water, 
the PVA leaches out and increases the membrane 
permeability, maintaining the integrity of the air 
compartment. Increase in molecular weight and 
concentration of PVA, resulted in enhancement of the 
floating properties of the system.   
Freeze-drying technique is also reported for the 
preparation of floating calcium alginate beads. Sodium 
alginate solution is added drop wise into the aqueous 
solution of calcium chloride, causing the instant gelation 
of the droplet surface, due to the formation of calcium 
alginate. The obtained beads are freeze-dried resulting in 
a porous structure, which aid in floating. The authors 
studied the behaviour of radio labeled floating beads and 
compared with non- floating beads in human volunteers 
using gamma scintigraphy. Prolonged gastric residence 
time of more than 5.5 h was observed for floating beads. 
The non-floating beads had a shorter residence time with 
a mean onset emptying time of 1h.   
A new multiple type of floating dosage system had 
developed having a pill in the core, composed of 
effervescent layers and swellable membrane layers 
coated on sustained release pills . The inner layer of 
effervescent agents containing sodium bicarbonate and 
tartaric acid was divided into 2 sublayers to avoid direct 
contact between the 2 agents. These sublayers were 
surrounded by a swellable polymer membrane containing 
polyvinyl acetate and purified shellac. When this system 
was immersed in the buffer at 37°C, it settled down and 
the solution permeated into the effervescent layer 
through the outer swellable membrane. CO2 was 
generated by the neutralization reaction between the 2 
effervescent agents, producing swollen pills (like 
balloons) with a density less than 1.0 g/ml.23    
c) Hollow Microspheres  
Hollow microspheres are considered as one of the most 
promising buoyant systems, as they possess the unique 
advantages of multiple unit systems as well as better 
floating properties, because of central hollow space 
inside the microsphere. The general techniques involved 
in their preparation include simple solvent evaporation 
and solvent diffusion and evaporation. The drug release 
and better floating properties mainly depend on the type 
of polymer, plasticizer and the solvents employed for the 
preparation. Polymers such as polycarbonate, Eudragit® 
Sand cellulose acetate were used in the preparation of 
hollow microspheres, and the drug release can be 
modulated by optimizing the polymer quantity and the 
polymer-plasticizer ratio. Sustained release floating 
microspheres using polycarbonate were developed, 
employing solvent evaporation technique. Aspirin, 
griseofulvin and p-nitroaniline were used as model 
drugs. Dispersed phase containing polycarbonate 
solution in dichloromethane, and micronized drug, was 
added to the dispersion medium containing sodium 
chloride, polyvinyl alcohol and methanol. The dispersion 
was stirred for 3-4h to assure the complete solvent 
evaporation, and the microspheres obtained were filtered, 
washed with coldwater and dried. The spherical and 
hollow nature of the microspheres was confirmed by 
Scanning electron microscopic studies. The microspheres 
showed a drug payload of more than 50%, and the 
amount of  drug incorporated is found to influence the 
particle size distribution and drug release. The larger 
proportion of bigger particles was seen at high drug 
loading, which can be attributed to the increased 
viscosity of the dispersed phase.23 
 
C. Raft Forming Systems 
 
Raft forming systems have received much attention for 
the delivery of antacids and drug delivery for 
gastrointestinal infections and disorders. The basic 
mechanism involved in the raft formation includes the 
formation of viscous cohesive gel in contact with gastric 
fluids, wherein each portion of the liquid swells forming 
a continuous layer called a raft. The raft floats because of 
the buoyancy created by the formation of CO2 and act as 
a barrier to prevent the reflux of gastric Contents like 
HCl and enzymes into the oesophagus. Usually, the 
system contains a gel forming agent and alkaline 
bicarbonates or carbonates responsible for the formation 
of to make the system less dense and float on the gastric 
fluids.24 
 
ADVANTAGES OF FDDS 
25, 26
  
 The gastro retentive systems are advantageous for 
drugs absorbed through the stomach, e.g. ferrous 
salts, antacids.  
 Acidic substances like aspirin cause irritation on the 
stomach wall when come in contact with it. Hence, 
hydro dynamically balanced systems (HBS) 
formulation may be useful for the administration of 
aspirin and other similar drugs.  
 Administration of prolongs release floating dosage 
forms, tablet or capsules, will result in dissolution of 
the drug in the gastric fluid. They dissolve in the 
gastric fluid would be available for absorption in the 
small intestine after emptying of the stomach 
contents. It is therefore expected that a drug will be 
fully absorbed from floating dosage forms if it 
remains in the solution form even at the alkaline pH 
of the intestine.  
 The gastro retentive systems are advantageous for 
drugs meant for local action in the stomach. e.g. 
antacids.  
 When there is a vigorous intestinal movement and a 
short transit time as might occur in certain type of 
diarrhoea, poor absorption is expected. Under such 
circumstances it may be advantageous to keep the 
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drug in floating condition in stomach to get a 
relatively better response.  
 FDDS improves patient compliance by decreasing 
dosing frequency.  
 Bioavailability enhances despite first pass effect 
because fluctuations in plasma drug          
concentration are avoided; a desirable plasma drug 
concentration is maintained by continuous drug 
release.  
 Better therapeutic effect of short half-life drugs can 
be achieved.  
 Gastric retention time is increased because of 
buoyancy.  
 Enhanced absorption of drugs which solubilise only 
in stomach.  
 Superior to single unit floating dosage forms as such 
microspheres releases drug uniformly and there is no 
risk of dose dumping.  
 Avoidance of gastric irritation, because of sustained 
release effect, floatability and uniform release of 
drug through multi particulate system. 
 
LIMITATIONS OF FDDS
27
  
 Floating system is not feasible for those drugs that 
have solubility or stability problem in G.I. tract.  
 These systems require a high level of fluid in the 
stomach for drug delivery to float and work 
efficiently-coat, water.  
 The drugs that are significantly absorbed through 
out gastrointestinal tract, which undergo significant 
first pass metabolism, are only desirable candidate.   
 Some drugs present in the floating system causes 
irritation to gastric mucosa. 
 
APPLICATIONS OF FDDS
28
  
Floating drug delivery offers several applications for 
drugs having poor bioavailability because of the narrow 
absorption window in the upper part of the 
gastrointestinal tract. It retains the dosage form at the site 
of absorption and thus enhances the bioavailability. 
These are summarized as follows. 
 Sustained Drug Delivery: HBS systems can 
remain in the stomach for long periods and hence 
can release the drug over a prolonged period of 
time. The problem of short gastric residence time 
encountered with an oral CR formulation hence can 
be overcome with these systems. These systems 
have a bulk density of <1 as a result of which they 
can float on the gastric contents. These systems are 
relatively large in size and passing from the pyloric 
opening is prohibited.   
Eg. Sustained release floating capsules of 
nicardipine hydrochloride were developed and 
were evaluated in vivo. The formulation compared 
with commercially available MICARD capsules 
using rabbits. Plasma concentration time curves 
showed a longer duration for administration (16 
hours) in the sustained release floating capsules as 
compared with conventional MICARD capsules (8 
hours). 
 Site-Specific Drug Delivery: These systems are 
particularly advantageous for drugs that are 
specifically absorbed from stomach or the proximal 
part of the small intestine, eg, riboflavin and 
furosemide.   
Eg. Furosemide is primarily absorbed from the 
stomach followed by the duodenum. It has been 
reported that a monolithic floating dosage form 
with prolonged gastric residence time was 
developed and the bioavailability was increased. 
AUC obtained with the floating tablets was 
approximately 1.8 times those of conventional 
furosemide tablets. 
 Absorption Enhancement: Drugs that have poor 
bioavailability because of site- specific absorption 
from the upper part of the gastrointestinal tract are 
potential candidates to be formulated as floating 
drug delivery systems, thereby maximizing their 
absorption. Eg. A significantly increase in the 
bioavailability of floating dosage forms(42.9%) 
could be achieved as compared with commercially 
available LASIX tablets (33.4%) and enteric coated 
LASIX-long product (29.5%). 
 
 
Table 1: List of Drugs Formulated as Single and Multiple Unit Forms of Floating Drug Delivery System
29 
 
Tablets Cholrpheniramine maleate, Theophylline, Furosemide, Ciprofloxacin, Captopril, Acetylsalicylic acid, 
Nimodipine, Amoxycillin trihydrate, Verapamil HCI, Isosorbide di nitrate, Sotalol, Isosorbide 
mononitrate, Aceraminophen, Ampicillin, Cinnarazine, Dilitiazem, Florouracil, Piretanide, 
Prednisolone, Riboflavin- 5`Phosphate. 
Capsules Nicardipine, L-Dopa and benserazide, chlordizepoxide HCI, Furosemide, Misoprostal, Diazepam, 
Propranlol, Urodeoxycholic acid. 
Microspheres Verapamil, Aspirin, Griseofulvin, and p-nitroanilline, Ketoprofen, Tranilast, Iboprufen, Terfenadine. 
Granules   Indomethacin, Diclofenac sodium, Prednisolone. 
Films Drug delivery device. Cinnarizine 
 
 
FORMULATUION ASPECTS OF FDDS 
The design of novel controlled release dosage forms 
should take into account three important criteria, viz., 
drug, delivery, and destination.  Preformulation studies 
help in studying the physiochemical properties of drugs. 
These properties include pKa, pH, solubility, and 
incompatibility. The solubility of a compound affects the 
choice of a controlled drug delivery system. If the 
compound has very low solubility (i.e. less 
than0.01mg/ml), it is inherently sustained. A drug has to 
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cross a variety of biological membrances in order to 
produce a therapeutic effect when it is administered to 
the gastrointestinal tract. Thus a partition coefficient of a 
drug is important in determining penetration of these 
membrane barriers by the drug. Compounds with very 
low partition coefficients will not easily penetrate these 
membranes, resulting in poor bioavailability. Acid-base 
hydrolysis and enzymatic degradation attack orally 
administered drugs. Compounds such as propantheline 
are unstable in small intestine. This results in decrease 
bioavailability when administered in controlled release 
delivery form. 
In case of oral drug delivery systems, the first destination 
is the gastrointestinal tract. From here the drug is 
absorbed and is taken to the site of action. Thus 
physiology of the gastrointestinal tract has a direct effect 
on the design of controlled release delivery systems. In 
addition, effects of disease conditions and co-
administered drugs also affect the design.30 
 Absorption window: site of absorption also favours 
the development of this formulation. 
 Shorter biological half-life: Ranitidine 
hydrochloride having shorter biological half life‟s 
favours for the formulations.  
 Solubility: Drug having better solubility in acidic 
environment and also having specific site of 
absorption in the upper part of the small intestine. 
Drug having stability at gastric pH. 
 Dose: drugs that are used locally in stomach like 
Ranitidine hydrochloride, famotidine (H2- receptor 
antagonist). It is widely used/prescribed in duodenal 
ulcers, gasric ulcers, zollinger ellisons syndrome, 
gastro oesophageal reflex disease and erosive 
esophagitis. 
 Others: due to certain more reasons like: 
conventional dosages forms having poor patient 
compliance, increase the chance of missing dose of a 
drug due to shorter half life of drugs for which 
frequent administration is necessary. In conventional 
dosages forms it is very difficult to maintain plasma 
concentration time profile in steady state manner 
due to missing of dose. The unavoidable fluctuations 
in the drug concentration may lead to under 
medication or overmedication. 
 
PHARMACOKINETIC AND PHARMACO- 
DYNAMIC ASPECTS OF FDDS  
The aim of this section is to delineate these aspects in 
order to suggest rational selection of drugs for which 
FDDS would be a beneficial strategy.31-34 
PHARMACOKINETIC ASPECTS  
 Absorption window: Validation that the drug is 
within the category of narrow absorption window 
agents currently various experimental techniques are 
available that permit us to verify the absorption 
properties of the tested molecule, to determine the 
mechanism of intestinal absorption and to elucidate 
the permeability at different regions of the GI tract. 
In the case of absorption by active transporters that 
are capacity limited, the efficacy of the transport 
activity may increase following sustained 
presentation of the drug to the transporting enzymes 
in comparison to non-control release mode of 
administration.  
 Enhanced bioavailability: Once it has been 
ascertained that the compound in question is defined 
as narrow absorption window, the possibility of 
improving bioavailability by continuous 
administration of the compound to the specific site 
should be tested. For example, we have found that 
certain bisphosphonates, including alendronate, are 
absorbed directly from the stomach. However, the 
magnitude of this pathway remains modest even in 
the case where the prolonged gastric retention of the 
bisphosphonate in rats is produced by experimental 
or surgical means. On the other hand, the 
bioavailability of control release (CR) floating 
systems of Riboflavin and Levodopa are 
significantly enhanced in comparison to 
administration of simple CR polymeric 
formulations. It may be concluded that several 
different processes, related to absorption and transit 
of the drug in the gastrointestinal tract, act 
concomitantly and influence the magnitude of drug 
absorption. Therefore, in vivo studies are necessary 
to determine the release profile of the drug from the 
dosage form that will provide enhanced 
bioavailability 
 Enhanced first pass biotransformation: In a 
similar fashion to increased efficacy of active 
transporters exhibiting capacity limited activity, the 
pre-systemic metabolism of the tested compound 
may be considerably increased when the drug is 
presented to the metabolic enzymes (cytochrome 
P450, in particular CYP3A4) in a sustained manner, 
rather than by a bolus input. 
 Improved bioavailability due to reduced P-
glycoprotein (P-gp) activity in the duodenum: In 
apparent contrast to the higher density of CYP3A4 
at the upper part of the intestine, P-gp mRNA levels 
increase longitudinally along the intestine such that 
the highest levels are located in the colon. Therefore, 
for drugs that are P-gp substrate and do not undergo 
oxidative metabolism, such as Digoxin, floating 
systems may elevate absorption compared to the 
immediate and CR dosage forms. 
 Reduced frequency of dosing: For drugs with 
relatively short biological half-life, sustained and 
slow input from control release floating system may 
result in a flip-flop pharmacokinetics and enable 
reduced dosing frequency. This feature is associated 
with improved patient compliance, and thereby 
improves therapy. 
 Targeted therapy for local ailments in the upper 
GIT: The prolonged and sustained administration of 
the drug from the floating systems to the stomach 
may be advantageous for local therapy in the 
stomach and the small intestine. 
 
PHARMACODYNAMIC ASPECTS  
 Reduced fluctuations of drug concentration: 
Continuous input of the drug following floating 
system administration produces blood drug 
concentrations within a narrower range compared to 
the immediate release dosage forms. Thus, 
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fluctuations in drug effects are minimized and 
concentration dependent adverse effects that are 
associated with peak concentrations can be 
prevented. This feature is of special importance for 
drugs with a narrow therapeutic index 
 Improved selectivity in receptor activation: 
Minimization of fluctuations in drug concentration 
also makes it possible to obtain certain selectivity in 
the elicited pharmacological effect of drugs that 
activate different types of receptors at different 
concentrations.  
 Reduced counter-activity of the body: In many 
cases, the pharmacological response, which 
intervenes with the natural physiologic processes, 
provokes a rebound activity of the body that 
minimizes drug activity. Slow input of the drug into 
the body was shown to minimize the counter activity 
leading to higher drug efficiency. 
 Minimized adverse activity at the colon: Retention 
of the drug in the GRDF at the stomach minimizes 
the amount of drug that reaches the colon. Thus, 
undesirable activities of the drug in colon may be 
prevented. This pharmacodynamic aspect provides 
the rationale for floating formulation for beta-lactam 
antibiotics that are absorbed only from the small 
intestine and presence in the colon leads to 
development of microorganisms.35 
 
EVALUATION TECHNIQUES FOR FDDS 
In vitro evaluation of floating tablets Evaluation was 
performed to assess the physicochemical properties and 
release characteristics of the developed formulations.    
I. Pre-compression parameters  
a) Angle of Repose
36
  
 The frictional forces in a loose powder or granules can 
be measured by angle of repose. This is the maximum 
angle possible between the surface of a pile of powder or 
granules and the horizontal plane.    
The granules were allowed to flow through the funnel 
fixed to a stand at definite height (h). The angle of repose 
was then calculated by measuring the height and radius 
of the heap of granules formed.  
                   tan ɵ  = h/r 
                   ɵ = tan-1 (h/r)  
 
Where, ɵ = angle of repose  
             h = height of the heap  
             r = radius of the heap  
The relationship between Angle of repose and powder 
flow is as follows in table 2. 
  
Table 2: Relationship between angle of repose and 
powder flow 
Angle of repose Powder flow 
< 25  
25-30  
30-40 
 > 40 
Excellent  
Good 
 Passable  
Very poor 
                                   
b) Compressibility Index  
The flowability of powder can be evaluated by 
comparing the bulk density (ρo) and tapped density (ρt) 
of powder and the rate at which it packed down. 
Compressibility index was calculated by –   
 
         Compressibility index (%) =   ρt – ρo/ ρt   x 100            
 
Where, ρo = Bulk density g/ml002E  
             ρt = Tapped density g/ml.   
II Post-compression parameters   
a) Shape of Tablets  
Compressed tablets were examined under the magnifying 
lens for the shape of the tablet.    
b) Tablet Dimensions  
Thickness and diameter were measured using a 
calibrated Vernier calliper. Three tablets of each 
formulation were picked randomly and thickness was 
measured individually.    
c) Hardness
37
  
Hardness indicates the ability of a tablet to withstand 
mechanical shocks while handling. The hardness of the 
tablets was determined using Monsanto hardness tester. 
It was expressed in kg/cm2. Three tablets were randomly 
picked and hardness of the tablets was determined.    
d) Friability test  
The friability of tablets was determined by using Roche 
Friabilator. It was expressed in percentage (%). Ten 
tablets were initially weighed (Winitial) and transferred 
into friabilator. The friabilator was operated at 25rpm for 
4 minutes or run up to 100 revolutions. The tablets were 
weighed again (Wfinal). The % friability was then 
calculated by –  
                                                 %F = 100 (1-Wfinal/Winitial)  
% Friability of tablets less than 1% was considered 
acceptable.    
e) Tablet Density 
38 
Tablet density was an important parameter for floating 
tablets. The tablet would floats only when its density was 
less than that of gastric fluid (1.004). The density was 
determined using following relationship.  
                                                                      
                           V = πr2h  
                           d = m/v  
 
Where, v = volume of tablet (cc)  
             r = radius of tablet (cm) 
             h = crown thickness of tablet (g/cc)   
            m = mass of tablet 
    
f) Weight Variation Test 
Ten tablets were selected randomly from each batch and 
weighed individually to check for weight variation. A 
little variation was allowed in the weight of a tablet by 
U.S. Pharmacopoeia. The following percentage deviation 
in weight variation was allowed show in table 3. 
Table 3: Percentage deviation in weight variation 
 
Average weight of a  
tablet 
Percent deviation 
 130 mg or less 10  
>130mg and <324mg 7.5 
324 mg or more 5 
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g) Buoyancy / Floating Test  
The time between introduction of dosage form and its 
buoyancy on the simulated gastric fluid and the time 
during which the dosage form remain buoyant were 
measured. The time taken for dosage form to emerge on 
surface of medium called Floating Lag Time (FLT) or 
Buoyancy Lag Time (BLT) and total duration of time by 
which dosage form remain buoyant is called Total 
Floating Time (TFT). 
 
h) Swelling Study  
The swelling behaviour of a dosage form was measured 
by studying its weight gain or water uptake. The 
dimensional changes could be measured in terms of the 
increase in tablet diameter and/or thickness over time. 
Water uptake was measured in terms of percent weight 
gain, as given by the equation.    
                                                
WU =      (Wt – W0)/ W0 x 100 
 
Where, Wt = Weight of dosage form at time t.  
             W0 = Initial weight of dosage form.   
 
j) In vitro drug release studies  
The test for buoyancy and in vitro drug release studies 
are usually carried out in simulated gastric and intestinal 
fluids maintained at 37oC. In practice, floating time is 
determined by using the USP dissolution apparatus 
containing 900ml of 0.1 HCl as a testing medium 
maintained at 37oC. The time required to float the HBS 
dosage form is noted as floating (or floatation) time. 
Dissolution tests are performed using the USP 
dissolution apparatus. Samples are withdrawn 
periodically from the dissolution medium, replenished 
with the same volume of fresh medium each time, and 
then analyzed for their drug contents after an appropriate 
dilution. Recent methodology as described in USP XXIII 
states that the dosage unit is allowed to sink to the 
bottom of the vessel before rotation of blade is started. A 
small, loose piece of non reactive material such as not 
more than a few turns of wire helix may be attached to 
the dosage units that would otherwise float. However, 
standard dissolution methods based on the USP or 
British Pharmacopoeia (BP) have been shown to be poor 
predictors of in vitro performance for floating dosage 
forms. The method, although based on the standard BP 
(1993)/ USP (1990) apparatus 2 methods, was modified 
such that paddle blades were positioned at the surface of 
the dissolution medium. The results obtained with this 
modified paddle method showed reproducible biphasic 
release profiles when paddle speeds were increased from 
70 to 100 rpm and the dissolution medium pH was varied 
from 6.0 to 8.0. The dissolution profile was also 
unaltered when the bile acid concentration in the 
dissolution medium was increased from 7 to 14mM. In 
contrast, the standard paddle or basket method, as 
described in the BP (1993) was unable to provide either 
sufficient mixing of the dissolution medium to disperse 
oily rapid release material or sufficient mechanical 
erosion of the SR component of the formulation. In 
additional studies, the authors modified a standard 
dissolution vessel for more reliable assessment of the 
performance of the floating dosage forms, particularly 
those which rely on an erosion mechanism for drug 
release. The result showed a more reproducible 
dissolution profile while eliminating the need for the 
positioning of the paddle blades at the surface of the 
dissolution medium, thereby simplifying sampling 
procedures and preventing the adhesion of dosage forms 
to the paddle blades. Nevertheless, the method retained 
its ability to differentiate between acceptable and 
unacceptable dissolution performance. The specific 
gravity of floating drug delivery system (FDDS) can be 
determined by the displacement method using analytical 
grade benzene as a displacing medium.39  
 
                  
              Table 4: Dosage Forms of FDDS with Examples of Various Drugs
40-42  
Sr. No Dosage Forms DRUGS 
1 Floating tablet Acetaaminophen, Acetylsalicylic acid, Ampicillin, Amoxicillin 
trihydrate, Atenolol, Captopril, Cinnerzine, Diltiazem, Fluorouracil, 
Isosorbide dinitrate, Isosorbide mononitrate, p-aminobenzoic acid 
2 Floating capsule Furosemide, L-DOPA, Benserazide, Nicardipine, Misoprostol, 
Propanolol, Pepstatin 
3 Floating microsphere Aspirin, Griseofulvin, p-nitro aniline, Ibuprofen, Terfinadine, 
Tranilast 
4 Floating granules Cinnerzine, p-aminobenzoic acid, prednisolon, quinidine gluconate. 
5 Powders Several basic drugs- Riboflavin phosphate, Sotalol, Theophylline 
6 Film Cinnerzine, p-aminobenzoic acid, prednisolon, quinidine gluconate 
7 Multiple unit floating  dosage form Clarithromycin, p-aminobenzoic acid 
8 Bilayer Tablet Misoprostal 
9 Foams/ Hollow Bodies Ibuprofen 
10 Floating controlled release capsule Levodopa, Benserazide 
11 Effervescent floating liquid alginate 
preparation 
Aluminium hydroxide, Magnesium carbonate 
12 Floating liquid alginate preparation Aluminium-Magnesium antacid 
13 Colloidal gel forming FDDS Ferrous sulphate 
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Table 5: Marketed Formulation of Floating Drug Delivery System
43-46 
Sr. 
No 
Brand Name Drug Dosage Form Company, Country 
1 Topalkan Al-Mg Antacid Floating liquid Alginate Preparation Pierre Fabre Drug, France 
2 Liquid 
Gavison 
Al(OH)3, Magnesium 
carbonate 
Efferervescent Floating Liquid 
Alginate Preparation 
Glaxo Smith Kline, India 
3 Valrelease Diazepam Floating  Capsule Hoffmann- LaRoche, USA 
4 Madopar Levodopa, Benserazide Floating Controlled Release Capsule Roche Products, USA 
5 Cifran OD Ciprofloxacin Gas- generating Floating Tablets Ranbaxy, India 
6 Conviron Ferrous sulphate Colloidal Gel Forming Capsule Ranbaxy, India 
7 Cytotec Misoprostal Bilayer Floating Capsule Pharmacia, USA 
8 Oflin OD® Ofloxacin Gas generating floating tablet Ranbaxy, India 
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